Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE versus DOCIVYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE versus DOCIVYX.
CEFTRIAXONE vs DOCIVYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
1-2 g IV/IM every 24 hours; maximum 4 g/day.
75 mg/m2 intravenously over 1 hour every 3 weeks.
None Documented
None Documented
Terminal half-life: 5.8-8.7 hours in adults; prolonged to 12-24 hours in neonates and 30-90 hours in severe renal impairment.
Clinical Note
moderateCeftriaxone + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftriaxone."
Clinical Note
moderateCeftriaxone + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftriaxone."
Clinical Note
moderateWarfarin + Ceftriaxone
"Warfarin may increase the anticoagulant activities of Ceftriaxone."
Clinical Note
moderatePhenprocoumon + Ceftriaxone
Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment.
Renal (33-67% unchanged) and biliary (up to 40%) with fecal elimination. In neonates, renal excretion is lower (~20%).
Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftriaxone."